Granules India Outlines Business Transformation and High-Value Growth Drivers
Granules India Ltd · Intimation · 27 Sept 2026, 1:41 am
Granules India Outlines Business Transformation and High-Value Growth Drivers Granules India scheduled a webinar on 29th Sep'26 with IIFL Capital to discuss its strategic transition beyond legacy generics. Formulations now generate ~75% of revenue, with legacy-5 portfolio dependence dropping from ~85% in FY23 to <50% in FY26. Future growth centers on controlled substances, complex formulations, injectables, oncology (with potential 180-day exclusivities from FY28), US FTF/Para IV opportunities, and its Senn-backed peptide CDMO platform targeting a USD 100m revenue opportunity over 4–5 years to drive margin expansion.
Original exchange filing (PDF)
More announcements from Granules India Ltd
- Schedule of Investor Meet · 11 Nov 2026
- Change in Corporate Office Address of Registrar and Share Transfer Agent (RTA) · 06 Nov 2026
- Transcript of the Earnings Conference Call for Q2 and the half year of FY27 · 06 Nov 2026
- Audio recording of the Earnings Conference call for Q2 and the half -year of FY27 · 03 Nov 2026
- Monitoring Agency Report for the quarter ended on September 30, 2026 · 02 Nov 2026
- Investor Presentation to Analysts/Investors · 02 Nov 2026
- Press Release · 02 Nov 2026
- Unaudited financial results for the second quarter and half year ended on September 30,2026 · 02 Nov 2026
